Akebia Therapeutics(us:AKBA)
1.85
+1.09%
Updated on 2024-12-23
Open:1.85
Close:1.85
High:1.87
Low:1.81
Pre Close:1.83
Volume:1.09M
Amount:1.99M
Turnover:0.50%
Shares:218.18M
MarketCap:402.54M
About Akebia Therapeutics Company
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Company Name: Akebia Therapeutics
Company Address: 245 First Street,Suite 1400
Employees: 167
Fiscar Year: 12-31
IPO Date: 2014-03-20
Website: http://www.akebia.com
CIK: 1517022
View all SEC Filings
About
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Address:245 First Street,Suite 1400
Website:http://www.akebia.com
Market Movers